Lucid Diagnostics Inc

+0.06 (+4.92%)
7:59:33 PM EDT: $1.30 +0.02 (+1.56%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)49.71M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.34 Million
Adjusted EPS-$0.33
See more estimates
10-Day MA$1.27
50-Day MA$1.59
200-Day MA$2.06
See more pivots

Lucid Diagnostics Inc Stock, NASDAQ:LUCD

One Grand Central Place, 60 East 42nd Street, New York, New York 10165
United States of America
Phone: +1.212.949.4319
Number of Employees:


Lucid Diagnostics, Inc. develops medical testing devices. It is a commercial-stage medical diagnostics technology company which focuses on gastroesophageal reflux disease (GERD), acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma (EAC). The firm's products include EsoCheck is a cell collection device that is designed to collect cells of a targeted region of the esophagus without the need for endoscopy and EsoGuard is a laboratory developed test which analyzes methylated biomarkers. The company was founded on May 8, 2018 and is headquartered in New York, NY.